The FDA is using a quantitative risk-based strategy as an early intervention in evaluating clinical trials of medical devices, said an official with the Center for Devices and Radiological Health. This method involves small and medium-sized institutional review boards as well as those "that have never been inspected or not in a very long time," the official said.

Full Story:

Related Summaries